Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study
Erişim
info:eu-repo/semantics/closedAccessTarih
2024Yazar
Şenocak Taşçı, ElifKutlu, Yasin
Ölmez, Ömer Fatih
Mutlu, Arda Ulaş
Gündoğdu, Yasemin
Seyyar, Mustafa
Şahin, Elif
Çabuk, Devrim
Majidova, Nargiz
Uğurlu, İrem
Demirci, Ayşe
Aydın, Dinçer
Çavdar, Eyyüp
Bayram, Selami
Yıldırım, Nilgün
Karataş, Fatih
Karakurt Eryılmaz, Melek
Çağlayan, Dilek
Menekşe, Serkan
Kut, Engin
Arak, Hacı
Keser, Murat
Sunar, Veli
Perkin, Perihan
Şakalar, Teoman
Oyan, Başak
Sönmez, Özlem
Özer, Leyla
Yıldız, İbrahim
Üst veri
Tüm öğe kaydını gösterKünye
Şenocak Taşçı, E., Kutlu, Y., Ölmez, Ö. F., Mutlu, A. U., Gündoğdu, Y., Seyyar, M. ... Yıldız, İ. (2024). Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study. Expert Opinion on Pharmacotherapy, (25)4, 477-484. http://dx.doi.org/10.1080/14656566.2024.2337261Özet
Background: Triple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine is being used as standard adjuvant treatment in residual TNBC. We aimed to investigate the real-life data regarding the efficacy of capecitabine in residual TNBC. Design and methods: In this retrospective multicenter study, TNBC patients with residual disease were evaluated. Patients, who received standard anthracycline and taxane-based NAC and adjuvant capecitabine were eligible. Overall survival (OS), disease free survival (DFS) and toxicity were analyzed. Results: 170 TNBC patients with residual disease were included. Of these, 62.9% were premenopausal. At the time of analysis, the recurrence rate was 30% and death rate was 18%. The 3-year DFS and OS were 66% and 74%, respectively. In patients treated with adjuvant capecitabine, residual node positive disease stood out as an independent predictor of DFS (p = 0.024) and OS (p = 0.032). Undergoing mastectomy and the presence of T2 residual tumor was independent predictors of DFS (p = 0.016) and OS (p = 0.006), respectively. Conclusion: The efficacy of capecitabine was found lower compared to previous studies. Selected patients may have further benefit from addition of capecitabine. The toxicity associated with capecitabine was found lower than anticipated.
WoS Q Kategorisi
Q3Scopus Q Kategorisi
Q2Kaynak
Expert Opinion on PharmacotherapyCilt
25Sayı
4Koleksiyonlar
- Makale Koleksiyonu [3691]
- PubMed İndeksli Yayınlar Koleksiyonu [4105]
- Scopus İndeksli Yayınlar Koleksiyonu [6383]
- WoS İndeksli Yayınlar Koleksiyonu [6506]